FXBM: GC-MS Analysis of Fraxinus Xanthoxyloides Bark Extract for Antidiabetic Activity

Mashal Shahzadi published a dataset on 2026-06-04 containing GC-MS and HPLC-MS analysis results for Fraxinus xanthoxyloides bark methanol extract (FXBM). The 13.5 KB Excel file details 17 identified compounds and reports in vitro inhibitory activities against α-amylase, α-glucosidase, and DPP4, alongside in vivo biochemical parameters from a rat study. The data supports research into the plant's potential as an anti-diabetic agent.

Use Cases

• Identifying bioactive compounds in plant extracts based on GC-MS and HPLC-MS analysis results.
• Comparing the inhibitory potency of different extract fractions against diabetes-related enzymes like α-amylase and DPP4.
• Correlating in vitro assay results with in vivo biochemical outcomes such as blood glucose and lipid profiles.
• Screening for specific phenolic compounds like gallic acid, catechin, and quercetin quantified via HPLC-DAD.

Strengths

• Quantifies 17 specific compounds from the extract, including percentage contributions of esters (17.9%), polyols (16.35%), and O-glycosides (12.24%).
• Includes precise quantitative results from HPLC-DAD analysis for five phenolic compounds (e.g., quercetin at 6.4 µg/mg).
• Reports specific in vivo biochemical parameters (e.g., HbA1c, triglycerides, LDL) showing statistically significant changes (p < 0.05).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (13.5 KB), indicating limited scope, likely containing summary results rather than raw experimental data.

Provenance

Source

Mashal Shahzadi via figshare

Collection Method

Data generated from laboratory GC-MS, HPLC-MS, in vitro enzymatic assays, and in vivo rat studies.

Freshness

Last updated 2026-06-04 17:27:06; freshness should be verified.